Late-Breaking Clinical Science

Dr. Alanna A. Morris joined the ECCRI faculty in 2013. Dr. Morris received her undergraduate degree in Biology from Xavier University of Louisiana, and her medical degree from the Harvard Medical School. She completed her residency at Brigham and Womens Hospital in Boston, Massachusetts. Subsequently, she came to Emory University to complete fellowships in general cardiology, and advanced heart failure and transplant. After completion of her fellowship training, she was appointed Assistant Professor of Medicine in the Division of Cardiology at Emory University School of Medicine, and spends her clinical time in the Emory Center for Heart Failure Therapy and Transplantation. She serves as the the Director of Heart Failure Research, and the Associate Program Director of the Clinical Investigator Track of the Cardiovascular Disease Fellowship Program. Dr. Morris research interests include studying the importance of non-modifiable risk factors such as race and gender that may contribute to excess disease in high risk populations, and identifying the role of biomarkers of oxidative stress (OS) and endothelial dysfunction in patients with heart failure with reduced ejection fraction (HFrEF). Her research examines the interface between biochemical markers of OS with vascular and endothelial dysfunction in HFrEF, and the importance of metabolomic signatures in determining HF progression. In particular, she also seeks to define race- and gender- based differences in these biochemical and vascular markers, and whether they contribute significantly to observed differences in HF morbidity and mortality. Finally, her research examines race- and gender-based differences in outcomes after heart transplantation and LVAD implantation.

Gregg W. Stone, MD, FACC, MSCAI is an interventional cardiologist and Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine (Cardiology) and Professor of Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 120 national and international multicenter randomized trials (many of which have led to new device approval or indications in the US), has authored more than 2000 manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. With a 2018 H-factor of 152, Dr. Stone was recently listed in Nature Medicine as one of the most prolific authors in science. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes, myocardial infarction and cardiogenic shock; drug-eluting stents and bioresorbable scaffolds; left main and complex coronary artery disease intervention; antiplatelet and antithrombotic pharmacotherapies; transcatheter valve repair and replacement; interventional hypertension and heart failure therapies; left atrial appendage closure; intravascular imaging (IVUS, OCT and NIRS); vulnerable plaque diagnosis and treatment; adjunctive interventional devices including atherectomy, distal embolic protection, thrombectomy, covered stents, chronic total occlusion devices, and brachytherapy; saphenous vein graft therapies; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone is the director of TCT, the world's largest symposium devoted to interventional cardiology and vascular medicine. Dr. Stone founded the annual National Interventional Cardiology Fellow's Course and Transcatheter Valve Therapies TVT), the Chronic Total Occlusion (CTO) Summit, and co-directs multiple other meetings in the US, China, Russia, Europe, S. Korea and elsewhere.